Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: A European Hematology Association Survey (EPICOVIDEHA)

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  • Maria Stefania Infante
  • Jon Salmanton-García
  • Ana Fernández-Cruz
  • Francesco Marchesi
  • Ozren Jaksic
  • Barbora Weinbergerová
  • Caroline Besson
  • Rafael F Duarte
  • Federico Itri
  • Toni Valković
  • Tomáš Szotkovski
  • Alessandro Busca
  • Anna Guidetti
  • Andreas Glenthøj
  • Graham P Collins
  • Valentina Bonuomo
  • Uluhan Sili
  • Guldane Cengiz Seval
  • Marina Machado
  • Raul Cordoba
  • Ola Blennow
  • Ghaith Abu-Zeinah
  • Sylvain Lamure
  • Austin Kulasekararaj
  • Iker Falces-Romero
  • Chiara Cattaneo
  • Jaap Van Doesum
  • Klára Piukovics
  • Ali S Omrani
  • Gabriele Magliano
  • Marie-Pierre Ledoux
  • Cristina de Ramon
  • Alba Cabirta
  • Luisa Verga
  • Alberto López-García
  • Maria Gomes Da Silva
  • Zlate Stojanoski
  • Stef Meers
  • Tobias Lahmer
  • Sonia Martín-Pérez
  • Julio Dávila-Vals
  • Jens Van Praet
  • Michail Samarkos
  • Yavuz M Bilgin
  • Linda Katharina Karlsson
  • Josip Batinić
  • Anna Nordlander
  • Martin Schönlein
  • Martin Hoenigl
  • Zdeněk Ráčil
  • Miloš Mladenović
  • Michaela Hanakova
  • Giovanni Paolo Maria Zambrotta
  • Nick De Jonge
  • Tatjana Adžić-Vukičević
  • Raquel Nunes-Rodrigues
  • Lucia Prezioso
  • Milan Navrátil
  • Monia Marchetti
  • Annarosa Cuccaro
  • Maria Calbacho
  • Antonio Giordano
  • Oliver A Cornely
  • José-Ángel Hernández-Rivas
  • Livio Pagano
Vis graf over relationer

Patients with lymphoproliferative diseases (LPD) are vulnerable to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Here, we describe and analyze the outcome of 366 adult patients with chronic lymphocytic leukemia (CLL) or non-Hodgkin Lymphoma (NHL) treated with targeted drugs and laboratory-confirmed COVID-19 diagnosed between February 2020 and January 2022. Median follow-up was 70.5 days (IQR 0-609). Most used targeted drugs were Bruton-kinase inhibitors (BKIs) (N= 201, 55%), anti-CD20 other than rituximab (N=61, 16%), BCL2 inhibitors (N=33, 9%) and lenalidomide (N=28, 8%).Only 16.2% of the patients were vaccinated with 2 or more doses of vaccine at the onset of COVID-19. Mortality was 24% (89/366) on day 30 and 36%(134/366) on the last day of follow-up. Age >75 years (p<0.001, HR 1.036), active malignancy (p<0.001, HR 2.215), severe COVID-19 (p=0.017, HR 2.270) and admission to ICU (p<0.001, HR 5.751) were risk factors for mortality at last day of follow up. There was no difference in OS rates in NHL vs CLL patients (p=0.306), nor in patients treated with or without BKIs (p=0.151). Mortality in ICU was 66% (CLL 61%, NHL 76%). Overall mortality rate decreased according to vaccination status, being 39% in unvaccinated patients, 32% and 26% in those having received one or two doses, respectively, and 20% in patients with a booster dose (p=0.245). Overall mortality rate dropped from 41% during the first semester of 2020 to 25% at the last semester of 2021. These results show increased severity and mortality from COVID-19 in LPDs patients treated with targeted drugs.

OriginalsprogEngelsk
TidsskriftFrontiers in Oncology
Vol/bind12
Sider (fra-til)992137
ISSN2234-943X
DOI
StatusUdgivet - 2022

Bibliografisk note

Copyright © 2022 Infante, Salmanton-García, Fernández-Cruz, Marchesi, Jaksic, Weinbergerová, Besson, Duarte, Itri, Valković, Szotkovski, Busca, Guidetti, Glenthøj, Collins, Bonuomo, Sili, Seval, Machado, Cordoba, Blennow, Abu-Zeinah, Lamure, Kulasekararaj, Falces-Romero, Cattaneo, Van Doesum, Piukovics, Omrani, Magliano, Ledoux, de Ramon, Cabirta, Verga, López-García, Da Silva, Stojanoski, Meers, Lahmer, Martín-Pérez, Dávila-Vals, Van Praet, Samarkos, Bilgin, Karlsson, Batinić, Nordlander, Schönlein, Hoenigl, Ráčil, Mladenović, Hanakova, Zambrotta, De Jonge, Adžić-Vukičević, Nunes-Rodrigues, Prezioso, Navrátil, Marchetti, Cuccaro, Calbacho, Giordano, Cornely, Hernández-Rivas and Pagano.

ID: 85881860